Jennison Associates
OMED

Jennison Associates’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Jennison Associates’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-89,546
Closed -$905K – 681
2016
Q1 		$905K Hold
89,546
– – ﹤0.01% 562
2015
Q4 		$2.02M Buy
+89,546
New +$1.83M ﹤0.01% 560

Other funds holding OMED

ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates's OMED Position: Q2 2016 in Review

Jennison Associates sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2016, closing a stake of 89,546 shares — an estimated $905K sold.

Jennison Associates first reported a position in OMED in Q4 2015 and held it in 2 quarters. The position peaked at $2.02M in Q4 2015. 84 funds tracked by Wall St. Rank hold OMED as of Q2 2016.

  • Jennison Associates reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Jennison Associates sold 89,546 OncoMed Pharmaceuticals, Inc. shares in Q2 2016, an estimated $905K.
  • Jennison Associates first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2015 and held it in 2 quarters.
  • Jennison Associates's OncoMed Pharmaceuticals, Inc. position peaked at $2.02M in Q4 2015.
  • 84 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2016.

Based on Jennison Associates's 13F filing for Q2 2016, filed 3 Aug 2016.